The transcription factor NF-kappa B: control of oncogenesis and cancer therapy resistance

Citation
Mw. Mayo et As. Baldwin, The transcription factor NF-kappa B: control of oncogenesis and cancer therapy resistance, BBA-REV CAN, 1470(2), 2000, pp. M55-M62
Citations number
80
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
ISSN journal
0304-419X → ACNP
Volume
1470
Issue
2
Year of publication
2000
Pages
M55 - M62
Database
ISI
SICI code
0304-419X(20000327)1470:2<M55:TTFNBC>2.0.ZU;2-P
Abstract
Discovered in 1986 as a DNA binding activity that recognized the immunoglob ulin light chain intronic enhancer, NF-kappa B has been studied intensively for its role in controlling expression of genes involved in immune and inf lammatory function [1,2]. However, more recently, NF-kappa B has been impli cated in controlling cell growth and oncogenesis. The link between NF-kappa B and cancer stems, in part, from the fact that this transcription factor is capable of inducing gene products that control proliferative responses a nd that suppress apoptotic cascades, such as those induced by tumor necrosi s factor (TNF), expression of oncoproteins, and genotoxic stress. This latt er observation is likely to be important in developing new approaches aimed at improving the efficacy of cancer chemotherapy. (C) 2000 Elsevier Scienc e B.V. All rights reserved.